Stock Events

Stock Events

Oculis 

€10.10
20
-€0.20-1.94% 11:02 Today

Statistics

Day High
10.2
Day Low
10.1
52W High
28.3
52W Low
8.96
Volume
-
Avg. Volume
-
Mkt Cap
560.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.52
-0.4
-0.29
-0.17
Expected EPS
-0.42801914625081
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-105.18MNet Income

Analyst Ratings

26.18Average Price Target
The highest estimate is 34.15.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CR5.STU. It's not an investment recommendation.
Microsoft
5
MSFT
NVIDIA
5
NVDA
Apple
4
AAPL
Meta Platforms
4
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals competes with Oculis in the ophthalmology space, particularly in treatments for eye diseases like age-related macular degeneration.
Novartis
NVS
Mkt Cap304.1B
Novartis is a major player in the development of drugs for eye conditions, directly competing with Oculis in the ophthalmic drug market.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie, through its acquisition of Allergan, has a strong presence in the eye care market, especially in treatments for conditions like dry eye, directly competing with Oculis.
Regenxbio
RGNX
Mkt Cap590.16M
REGENXBIO is involved in gene therapy for ocular diseases, offering innovative treatments that compete with Oculis's drug development efforts.
Bausch Health Companies
BHC
Mkt Cap2.45B
Bausch Health Companies, through its eye health division, competes in the same space as Oculis, particularly in treatments for eye diseases.
Rogers
ROG
Mkt Cap2.28B
Roche, with its ophthalmology division, competes in developing treatments for eye diseases, including macular degeneration and diabetic retinopathy, areas Oculis is also targeting.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline has initiatives in developing treatments for eye conditions, potentially competing with Oculis in the broader ophthalmology market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca, through its acquisition of Alexion Pharmaceuticals, competes in the space of treatments for diseases including those affecting the eye, aligning as a competitor to Oculis.

About

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Show more...
CEO
Riad Sherif
Employees
60
Country
Switzerland
ISIN
CH1242303498
WKN
000A3D8QG

Listings

STU
DE
CR5.STU
XNAS
US
OCS
XNAS
US
OCSAW
F
DE
CR5.F

0 Comments

Share your thoughts

FAQ

What is Oculis stock price today?▼
The current price of CR5.STU is €10.10 EUR — it has decreased by -1.94% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.
What is Oculis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Oculis stocks are traded under the ticker CR5.STU.
Is Oculis stock price growing?▼
CR5.STU stock has fallen by -1.94% compared to the previous week, the month change is a -5.61% fall, over the last year Oculis has showed a -30.1% decrease.
What is Oculis market cap?▼
Today Oculis has the market capitalization of 560.83M
When is the next Oculis earnings date?▼
Oculis is going to release the next earnings report on November 05, 2026.
What were Oculis earnings last quarter?▼
CR5.STU earnings for the last quarter are -0.17 EUR per share, whereas the estimation was -0.42 EUR resulting in a +58.76% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oculis revenue for the last year?▼
Oculis revenue for the last year amounts to 0 EUR.
What is Oculis net income for the last year?▼
CR5.STU net income for the last year is -105.18M EUR.
How many employees does Oculis have?▼
As of September 07, 2026, the company has 60 employees.
In which sector is Oculis located?▼
Oculis operates in the Health & Wellness sector.
When did Oculis complete a stock split?▼
Oculis has not had any recent stock splits.
Where is Oculis headquartered?▼
Oculis is headquartered in Zug, Switzerland.